Sports physician contrasts semaglutide evidence with BPC-157 and TB-500 claims
Jordan Metzl says recovery peptides sold through wellness clinics rest largely on animal work and very small human studies.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 4 08:30 ETSource: AOL.ca
The wire
- 01In a September 28 Washington Post column, Hospital for Special Surgery physician Jordan Metzl separated trial-backed peptides such as semaglutide from marketed recovery compounds including BPC-157, TB-500, CJC-1295 and ipamorelin.
- 02Metzl cites a 2024 New England Journal of Medicine trial in which patients with obesity and knee osteoarthritis lost 13.7 percent of body weight over 68 weeks versus 3.2 percent on placebo, with less knee pain.
- 03He notes FDA concerns over scarce human exposure data and stresses that compounding access, even physician-supervised, is not equivalent to FDA approval or its manufacturing oversight.
From the source
Read at aol.caShould You Take Peptides for Recovery? A Doctor Explains the Risks
Peptides have become one of the hottest subjects in the modern fitness and longevity world, promising everything from faster recovery and more muscle to less body fat, better sleep, and fewer aches. But Jordan D. Metzl, MD, a sports medicine physician at New York’s Hospital for Special Surgery, says the growing enthusiasm needs to be separated from what medicine actually knows.
